Plant Name: Atalantia wightii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; ADORA1; ADORA3; ADORA2A; ADRA2C; ADRA2A; | |
| TSHR; NMUR2; | |
| RECQL; TDP1; BLM; PKM; ADK; HPGD; AKR1B1; HSD17B10; ALOX15; ALDH1A1; GFER; USP2; APEX1; POLB; | |
| ACHE; GAA; | |
| DUSP3; | |
| AKT1; MET; GSK3B; CSNK2A1; SRC; IGF1R; PTK2; BRAF; AURKB; AURKA; FLT4; EPHB4; MAP3K8; TEK; PDGFRB; INSR; PLK4; MAPK1; ERBB2; EGFR; NUAK1; KDR; PLK1; | |
| CA7; CA3; CA14; CA5B; CA5A; CA1; CA12; CA9; CA13; CA4; CA6; CA2; | |
| KDM4E; | |
| PTGS1; PTGS2; | |
| CASP7; CASP1; | |
| BACE1; | |
| STAT6; STAT1; TP53; | |
| KMT2A; | |
| FUT7; | |
| SLC28A2; SLC28A3; SLC28A1; SLC22A6; | |
| SMAD3; LMNA; MAPT; HBB; THPO; RAB9A; NPC1; HSPA1A; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
| Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
| Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
| Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | P42224 | CHEMBL6101 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.087E-11 | 4.227E-09 | ADK, AKT1, AURKA, AURKB, BLM, BRAF, CSNK2A1, EGFR, EPHB4, ERBB2, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MAPK1, MET, NUAK1, PDGFRB, PKM, PLK1, PLK4, PTK2, RECQL, SRC, TEK, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.054E-09 | 2.087E-07 | ADORA1, ADRA2A, CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, TEK, TSHR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.334E-09 | 1.344E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, HBB, PTGS1, PTGS2, SRC |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 3.408E-08 | 4.470E-06 | AKT1, EGFR, HBB, INSR, PTGS2, SMAD3 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.743E-08 | 4.880E-06 | EGFR, ERBB2, INSR, MET, PDGFRB, PTK2, SRC, TEK, THPO |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 5.454E-08 | 6.865E-06 | EGFR, ERBB2, INSR, KDR |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.082E-08 | 7.482E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, HBB |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 6.334E-08 | 7.749E-06 | AKR1B1, AKT1, EGFR, HPGD, PDGFRB, PTGS2, STAT1 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 7.958E-08 | 9.418E-06 | EGFR, IGF1R, INSR, KDR, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 8.256E-08 | 9.665E-06 | AKT1, APEX1, BLM, CASP7, CYP1A1, CYP1B1, EGFR, MAPK1, NPC1, PTGS2, SRC, STAT1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 9.058E-08 | 1.055E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.654E-07 | 1.783E-05 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.994E-07 | 3.075E-05 | ADORA1, ADORA2A, ADRA2A, AURKB, CA2, CA7, EGFR, KDR, MAPK1, NPC1, PTGS2, SRC, STAT1 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 3.444E-07 | 3.472E-05 | ALOX15, BRAF, EGFR, FLT4, KDR, PDGFRB, SRC, TEK, THPO |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 4.403E-07 | 4.339E-05 | ADRA2A, AKT1, AURKA, BRAF, DUSP3, EGFR, GSK3B, MAPK1, PDGFRB, PLK1, PTK2, SMAD3, SRC, TP53 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 4.909E-07 | 4.772E-05 | ADRA2A, ADRA2C, AKT1, INSR, SRC |
| BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 5.215E-07 | 5.025E-05 | ADORA2A, AKT1, CASP1, KDR, MAPT, SRC |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 9.915E-07 | 8.885E-05 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, EGFR, EPHB4, ERBB2, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPC1, PDGFRB, TEK, TSHR |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.088E-06 | 9.670E-05 | ADORA2A, AURKB, CA2, CA7, EGFR, MAPK1, NPC1, PTGS2, STAT1 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.571E-06 | 1.334E-04 | ALOX15, EGFR, ERBB2, PDGFRB, SMAD3, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.937E-06 | 1.585E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | Unclassified; | GO:0006461; protein complex assembly | 2.411E-06 | 1.909E-04 | ACHE, BLM, BRAF, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, KMT2A, MAPT, PKM, PTK2, SLC22A6, SMAD3, SRC, TEK, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.482E-06 | 1.937E-04 | CYP1A1, PDGFRB, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.482E-06 | 1.937E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 2.813E-06 | 2.142E-04 | ACHE, ALDH1A1, EGFR, IGF1R, INSR, PKM |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 3.378E-06 | 2.493E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.646E-06 | 2.656E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 4.661E-06 | 3.306E-04 | ADORA2A, AKT1, CASP1, CASP7, CYP1B1, GSK3B, HPGD, MAPT, PDGFRB, PTGS2, SMAD3, SRC, TP53 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.875E-06 | 3.446E-04 | BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, KMT2A, SMAD3, TP53 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 5.820E-06 | 3.998E-04 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, BACE1, EPHB4, FLT4, GPR35, IGF1R, INSR, KDR, MET, NPC1, SLC22A6, SLC28A1, SLC28A2, SLC28A3, TEK, TSHR |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 6.927E-06 | 4.641E-04 | ADRA2A, AKR1B1, AKT1, CA12, CA2, CA7, EGFR, GPR35, INSR, MAPK1, MET, NMUR2, NPC1, SMAD3, STAT1, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 8.052E-06 | 5.207E-04 | ADORA2A, EGFR, MAPT |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 8.052E-06 | 5.207E-04 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 8.052E-06 | 5.207E-04 | ADORA1, ADORA2A, ADORA3 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 8.118E-06 | 5.223E-04 | ADK, AKR1B1, AKT1, ALDH1A1, ALOX15, AURKA, AURKB, BLM, BRAF, CA1, CA13, CA2, CA3, CA7, CASP1, CASP7, CSNK2A1, DUSP3, EPHB4, ERBB2, GFER, GSK3B, HBB, HPGD, HSPA1A, KMT2A, LMNA, MAP3K8, MAPK1, MAPT, PKM, PLK1, PLK4, PTK2, RAB9A, SMAD3, SMN1, SMN2, SRC, STAT1, STAT6, TP53 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 8.283E-06 | 5.289E-04 | AKT1, MAPT, STAT1, TP53 |
| BP | GO:0009987; cellular process | GO:0070507; regulation of microtubule cytoskeleton organization | 9.454E-06 | 5.950E-04 | AURKA, GSK3B, HSPA1A, MAPT, MET, PLK1, PLK4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.850E-06 | 6.163E-04 | ALOX15, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, HBB |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.101E-05 | 6.752E-04 | PDGFRB, PTK2, SRC, TEK |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.237E-05 | 7.521E-04 | AKT1, APEX1, AURKB, CYP1A1, PDGFRB, POLB, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.259E-05 | 7.638E-04 | AKT1, CYP1A2, EGFR, MAPK1 |
| BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 1.434E-05 | 8.579E-04 | EPHB4, GAA, INSR, PTK2 |
| BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 1.626E-05 | 9.493E-04 | ADRA2C, AKT1, EGFR, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.196E-26 | 4.781E-22 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 1.826E-05 | 1.062E-03 | ADRA2C, AKT1, AURKA, BRAF, CA2, CYP1B1, INSR, KDR, LMNA, MAPT, PDGFRB, PTGS2, SMAD3, SRC, STAT1, STAT6, TEK, THPO |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.830E-05 | 1.062E-03 | AKT1, AURKA, AURKB, BLM, CSNK2A1, NUAK1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 1.921E-05 | 1.110E-03 | AKR1B1, AKT1, EGFR, KDR, PDGFRB, PTGS2, SLC22A6, SRC, TP53 |
| CC | GO:0016020; membrane | GO:0005901; caveola | 2.006E-05 | 1.152E-03 | INSR, MAPK1, PTGS2, SLC22A6, SRC |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.088E-05 | 1.190E-03 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 2.147E-05 | 1.205E-03 | EGFR, NMUR2 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 2.147E-05 | 1.205E-03 | SLC28A2, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.147E-05 | 1.205E-03 | APEX1, POLB |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 2.147E-05 | 1.205E-03 | PTGS1, PTGS2 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 2.147E-05 | 1.205E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 2.147E-05 | 1.205E-03 | SLC28A2, SLC28A3 |
| MF | Unclassified; | GO:0004872; receptor activity | 2.479E-05 | 1.367E-03 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, EGFR, EPHB4, ERBB2, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPC1, PDGFRB, TEK, TSHR |
| BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 2.591E-05 | 1.418E-03 | CYP1B1, EPHB4, FLT4, KDR, PDGFRB, PTGS2, PTK2, TEK |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 2.705E-05 | 1.465E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 2.882E-05 | 1.557E-03 | AKT1, CASP1, CASP7, PTK2 |
| BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 3.805E-05 | 1.997E-03 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
| BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 4.274E-05 | 2.185E-03 | FLT4, KDR, PDGFRB |
| MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 4.308E-05 | 2.197E-03 | AKT1, AURKA, AURKB, MAPK1 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 4.532E-05 | 2.306E-03 | ACHE, AKR1B1, APEX1, AURKA, CA4, EGFR, ERBB2, HSPA1A, NPC1, SRC, STAT1, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0045986; negative regulation of smooth muscle contraction | 5.242E-05 | 2.583E-03 | ADORA1, ADRA2C, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 5.242E-05 | 2.583E-03 | ALOX15, HPGD, PTGS2 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 5.242E-05 | 2.583E-03 | ADORA1, ADORA2A, MAPT |
| BP | GO:0008152; metabolic process | GO:0019637; organophosphate metabolic process | 6.071E-05 | 2.925E-03 | ACHE, ADK, ADORA2A, ALDH1A1, ALOX15, CSNK2A1, EGFR, ERBB2, HSPA1A, MAPK1, MET, PDGFRB, PKM, PTGS2 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 6.421E-05 | 3.007E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.421E-05 | 3.007E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 6.421E-05 | 3.007E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 6.421E-05 | 3.007E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.421E-05 | 3.007E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 6.421E-05 | 3.007E-03 | ADRA2A, ADRA2C |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 6.421E-05 | 3.007E-03 | ADORA1, ADORA2A |
| BP | GO:0009987; cellular process | GO:0051262; protein tetramerization | 6.455E-05 | 3.016E-03 | ACHE, HSD17B10, IGF1R, INSR, PKM, TP53 |
| BP | GO:0002376; immune system process | GO:0002682; regulation of immune system process | 6.756E-05 | 3.130E-03 | ADORA1, ADORA2A, AKT1, ALOX15, BRAF, CA2, DUSP3, ERBB2, HSPA1A, KMT2A, MAP3K8, MAPK1, PTK2, SMAD3, SRC, STAT1, STAT6, THPO, TP53 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 7.747E-05 | 3.522E-03 | ACHE, ADRA2A, ADRA2C, AKT1, BLM, FLT4, HPGD, KMT2A, MAPT, PTGS2, SLC22A6, SMAD3, STAT1 |
| MF | Unclassified; | GO:0032403; protein complex binding | 7.747E-05 | 3.522E-03 | ACHE, ADORA1, ADRA2A, APEX1, EGFR, IGF1R, INSR, KDR, PKM, PLK1, SMAD3, SRC, TSHR |
| BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 8.354E-05 | 3.743E-03 | ADORA1, ADORA2A, BRAF, KMT2A, MAPK1, PTGS2 |
| BP | GO:0032501; multicellular organismal process | GO:0003014; renal system process | 8.594E-05 | 3.842E-03 | ADORA1, ADORA2A, AKR1B1, HBB, SLC22A6 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 1.014E-04 | 4.426E-03 | ADORA1, ADORA2A, ADORA3, CYP1B1, ERBB2, HSPA1A, KMT2A, LMNA, PTGS2, SMAD3, STAT1, TP53 |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.054E-04 | 4.570E-03 | ADORA1, ADORA2A, ADRA2A, ADRA2C, AURKA, BRAF, EGFR, ERBB2, SMAD3, TP53 |
| BP | GO:0009987; cellular process | GO:0009968; negative regulation of signal transduction | 1.085E-04 | 4.687E-03 | ADRA2A, AKT1, BRAF, DUSP3, EGFR, ERBB2, GSK3B, HSPA1A, IGF1R, LMNA, MET, PDGFRB, PTGS2, SMAD3, SRC, STAT1 |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 1.084E-04 | 4.687E-03 | AURKA, AURKB, PLK1, POLB |
| BP | GO:0007610; behavior | GO:0007611; learning or memory | 1.144E-04 | 4.874E-03 | BRAF, EGFR, INSR, KMT2A, MAPK1, MAPT, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 1.224E-04 | 5.166E-03 | CA2, PTGS2, SRC |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.256E-04 | 5.289E-03 | AKT1, LMNA, PTGS2, SRC, TP53 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.280E-04 | 5.310E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.280E-04 | 5.310E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.280E-04 | 5.310E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.280E-04 | 5.310E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0032795; heterotrimeric G-protein binding | 1.280E-04 | 5.310E-03 | ADORA1, ADRA2A |
| CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.294E-04 | 5.359E-03 | ADRA2A, EGFR, ERBB2, FLT4, IGF1R, INSR, SMAD3, TSHR |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.305E-04 | 5.390E-03 | BRAF, KDR, KMT2A, MAPK1, POLB, TEK |
| BP | GO:0008152; metabolic process | GO:0050995; negative regulation of lipid catabolic process | 1.413E-04 | 5.772E-03 | ADORA1, ADRA2A, AKT1 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 1.500E-04 | 6.116E-03 | AKR1B1, ALDH1A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0051345; positive regulation of hydrolase activity | 1.597E-04 | 6.441E-03 | AKT1, ALDH1A1, CASP1, CASP7, EGFR, ERBB2, GSK3B, HSPA1A, MAPT, NMUR2, PDGFRB, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.619E-04 | 6.469E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0097305; response to alcohol | 1.632E-04 | 6.488E-03 | AKT1, BLM, CA3, HPGD, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.635E-04 | 6.488E-03 | ADRA2A, ADRA2C, AKT1, MAPK1, SRC |
| BP | GO:0065007; biological regulation | GO:0031647; regulation of protein stability | 1.636E-04 | 6.488E-03 | AURKA, HSPA1A, MAPK1, PLK1, SMAD3, SRC, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0030878; thyroid gland development | 1.844E-04 | 7.181E-03 | BRAF, MAPK1, SMAD3 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.877E-04 | 7.274E-03 | AKR1B1, APEX1, CYP1B1, STAT6 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.076E-04 | 7.988E-03 | ADK, AKR1B1, AKT1, APEX1, AURKA, AURKB, BLM, CASP7, CSNK2A1, DUSP3, GSK3B, HPGD, HSPA1A, KMT2A, LMNA, MAPK1, NUAK1, PLK1, POLB, RECQL, SMAD3, SMN1, SMN2, SRC, STAT1, STAT6, TP53, USP2 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.127E-04 | 8.029E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 2.127E-04 | 8.029E-03 | BLM, RECQL |
| CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 2.127E-04 | 8.029E-03 | AURKA, AURKB |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 2.262E-04 | 8.491E-03 | ACHE, ADORA1, BRAF, PTGS2 |
| BP | GO:0008152; metabolic process | GO:2000573; positive regulation of DNA biosynthetic process | 2.262E-04 | 8.491E-03 | AURKB, MAPK1, PDGFRB, SRC |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 2.270E-04 | 8.507E-03 | ADRA2C, AKT1, BRAF, CA2, CYP1B1, EGFR, ERBB2, GSK3B, INSR, KDR, KMT2A, MAPT, PDGFRB, PTGS2, PTK2, SMAD3, SRC, STAT1, STAT6, TEK, THPO |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 2.547E-04 | 9.354E-03 | KDR, PDGFRB, PTK2, TEK |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 2.547E-04 | 9.354E-03 | EGFR, ERBB2, MET, PDGFRB |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 2.639E-04 | 9.672E-03 | CYP1B1, FLT4, PTGS2 |
| MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 2.700E-04 | 9.879E-03 | APEX1, BLM, POLB, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.124E-21 | 9.933E-17 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.522E-18 | 2.840E-14 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.953E-25 | 3.515E-23 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 6.418E-12 | 5.776E-10 | PDGFRB; GSK3B; SRC; FLT4; BRAF; PTK2; EGFR; IGF1R; ERBB2; KDR; AKT1; MAPK1; MET |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.114E-11 | 6.684E-10 | PDGFRB; SRC; INSR; FLT4; BRAF; EGFR; IGF1R; ADORA2A; KDR; AKT1; MAPK1; TEK; MET |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.371E-11 | 1.967E-09 | SMAD3; CSNK2A1; SRC; INSR; ERBB2; MAPK1; MET; EGFR; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.379E-10 | 8.566E-09 | PDGFRB; GSK3B; ERBB2; AKT1; MAPK1; BRAF; TP53; EGFR; IGF1R |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.681E-10 | 1.653E-08 | SMAD3; STAT1; ERBB2; AKT1; MAPK1; BRAF; TP53; EGFR |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.699E-09 | 4.858E-08 | PDGFRB; GSK3B; SMAD3; STAT1; BRAF; PTGS2; EGFR; PTK2; IGF1R; ERBB2; AKT1; MAPK1; MET; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.856E-09 | 3.711E-08 | SRC; ERBB2; KDR; AKT1; MAPK1; BRAF; TP53; MET; PTK2; EGFR; IGF1R |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.428E-10 | 1.653E-08 | PDGFRB; PKM; ERBB2; AKT1; MAPK1; TP53; MET; EGFR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.033E-09 | 2.325E-08 | PDGFRB; AKT1; MAPK1; BRAF; TP53; MET; EGFR; IGF1R |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.135E-09 | 6.203E-08 | PDGFRB; GSK3B; INSR; FLT4; PTK2; EGFR; IGF1R; KDR; AKT1; MAPK1; TEK; TP53; MET |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.345E-09 | 5.473E-08 | GSK3B; ERBB2; AKT1; MAPK1; BRAF; TP53; EGFR |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 5.353E-09 | 7.412E-08 | GSK3B; SRC; ERBB2; AKT1; MAPK1; BRAF; EGFR; PTK2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.660E-08 | 1.992E-07 | PDGFRB; AKT1; MAPK1; BRAF; TP53; EGFR; IGF1R |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 8.673E-09 | 1.115E-07 | PLK4; SMAD3; INSR; PLK1; AKT1; MAPK1; BRAF; EGFR; IGF1R |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 7.534E-08 | 7.978E-07 | PDGFRB; INSR; FLT4; KDR; AKT1; MAPK1; TEK; MET; EGFR; IGF1R |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.226E-07 | 2.003E-06 | PDGFRB; DUSP3; AKT1; MAPK1; BRAF; MAP3K8; MAPT; TP53; EGFR; HSPA1A |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.901E-07 | 1.801E-06 | ERBB2; AKT1; MAPK1; BRAF; TP53; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.778E-08 | 3.125E-07 | SRC; ERBB2; MAPK1; BRAF; TP53; EGFR |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.901E-07 | 1.801E-06 | INSR; ADORA1; AKT1; PTGS2; TSHR; PTGS1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 3.192E-07 | 2.736E-06 | SRC; KDR; AKT1; MAPK1; PTGS2; PTK2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.115E-07 | 3.221E-06 | INSR; ERBB2; AKT1; MAPK1; TEK; EGFR; IGF1R |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.522E-07 | 2.881E-06 | GSK3B; SMAD3; AKT1; MAPK1; BRAF; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.317E-06 | 1.668E-05 | GSK3B; STAT1; AKT1; MAPK1; BRAF; TP53; EGFR |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 2.689E-06 | 1.862E-05 | GSK3B; CSNK2A1; STAT1; AKT1; RAB9A; TP53; HSPA1A |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.308E-06 | 2.769E-05 | SMAD3; STAT1; SRC; AKT1; MAPK1; STAT6; TP53 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.042E-05 | 6.251E-05 | ADORA3; INSR; ADORA1; AKT1; MAPK1; ADRA2C; ADRA2A |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.867E-06 | 1.400E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.145E-05 | 6.648E-05 | ALOX15; MAPK1; BRAF; CYP2C19; PTGS2; PTGS1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.543E-05 | 8.681E-05 | GSK3B; STAT1; SRC; AKT1; MAPK1; TP53 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.168E-05 | 1.115E-04 | GSK3B; STAT1; SRC; AKT1; MAPK1; BRAF; PTK2 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 3.555E-05 | 1.777E-04 | ADORA2A; GPR35; ADORA3; ADORA1; NMUR2; ADRA2C; ADRA2A; TSHR |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.979E-06 | 1.986E-05 | INSR; CYP1A1; CYP1B1; PTGS2; IGF1R |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.812E-05 | 2.828E-04 | PDGFRB; ERBB2; CYP1B1; MAPK1; PTGS2; TP53; MET; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.820E-05 | 9.926E-05 | GSK3B; STAT1; SRC; AKT1; MAPK1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.947E-05 | 1.031E-04 | SMAD3; AKT1; MAPK1; BRAF; TP53 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 8.058E-05 | 3.817E-04 | PLK1; AKT1; MAPK1; BRAF; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 8.456E-05 | 3.903E-04 | SRC; AKT1; MAPK1; EGFR; HSPA1A |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.117E-04 | 5.025E-04 | BACE1; GSK3B; CASP7; MAPK1; MAPT; HSD17B10 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.396E-04 | 5.845E-04 | GSK3B; STAT1; CASP1; AKT1; MAPK1; HSPA1A |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.686E-04 | 6.744E-04 | SMAD3; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.392E-04 | 5.845E-04 | CASP7; AKT1; MAPK1; MAP3K8; PTGS2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.628E-04 | 6.660E-04 | HPGD; KMT2A; TP53; MET; PTK2; IGF1R |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.092E-04 | 7.578E-04 | GSK3B; AKT1; MAPK1; BRAF; TP53 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.800E-04 | 9.508E-04 | ADORA2A; ADORA1; AKT1; MAPK1; BRAF; TSHR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.092E-04 | 7.578E-04 | ADORA3; ADORA1; AKT1; MAPK1; TP53 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 4.126E-04 | 1.304E-03 | PDGFRB; SRC; MAPK1; BRAF; PTK2; EGFR |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.267E-04 | 1.324E-03 | CASP7; LMNA; AKT1; MAPK1; TP53 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 2.723E-04 | 9.427E-04 | GSK3B; MAPK1; MET; PTK2; EPHB4 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 4.129E-04 | 1.304E-03 | GSK3B; INSR; AKT1; MAPK1; BRAF |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 4.853E-04 | 1.456E-03 | PDGFRB; INSR; AKT1; MAPK1; EGFR |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 4.553E-04 | 1.389E-03 | GSK3B; SMAD3; AKT1; MAPK1; IGF1R |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.096E-03 | 3.016E-03 | PDGFRB; POLB; GSK3B; SMAD3; AKT1; TP53 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.234E-03 | 3.232E-03 | GAA; ALOX15; ADK; AKR1B1; PTGS2; CYP2C19; CYP3A4; HSD17B10; PTGS1; FUT7; PKM; CYP1A2; ALDH1A1; CYP1A1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.982E-04 | 7.578E-04 | INSR; AKT1; HSPA1A; IGF1R |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.351E-04 | 5.845E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.257E-03 | 3.232E-03 | PDGFRB; THPO; FLT4; KDR; MET; EGFR |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.122E-03 | 3.016E-03 | SMAD3; STAT1; AKT1; MAPK1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.233E-04 | 7.881E-04 | AKT1; MAPK1; BRAF; MET |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.752E-04 | 6.857E-04 | ALOX15; CYP2C19; PTGS2; PTGS1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 8.586E-04 | 2.415E-03 | INSR; AKT1; TP53; IGF1R |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.195E-03 | 5.199E-03 | GSK3B; CSNK2A1; AKT1; TP53; HSPA1A |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.122E-03 | 3.016E-03 | PDGFRB; AKT1; MAPK1; EGFR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.105E-04 | 7.578E-04 | CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 6.145E-04 | 1.813E-03 | AKT1; PTGS2; TP53; PTK2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.293E-04 | 1.078E-03 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.251E-03 | 3.232E-03 | GSK3B; AKT1; MAPK1; MAP3K8 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.340E-03 | 5.331E-03 | POLB; PKM; SRC; MAPK1; TP53 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 6.701E-04 | 1.946E-03 | PDGFRB; SRC; MAPK1; EGFR |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.343E-03 | 3.356E-03 | STAT1; AKT1; MAPK1; MAP3K8 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.248E-03 | 5.255E-03 | SRC; AKT1; MAPK1; PTGS1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.991E-03 | 4.843E-03 | STAT1; AKT1; MAPK1; HSPA1A |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 2.316E-03 | 5.331E-03 | PLK1; MAPK1; AURKA; IGF1R |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.355E-06 | 5.186E-05 | CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.882E-03 | 8.125E-03 | GSK3B; SMAD3; CSNK2A1; TP53 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.385E-03 | 5.366E-03 | GSK3B; SMAD3; PLK1; TP53 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 4.827E-03 | 9.548E-03 | GSK3B; CASP7; INSR; AKT1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 5.661E-03 | 1.084E-02 | THPO; STAT1; AKT1; STAT6 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 5.661E-03 | 1.084E-02 | SRC; MAPK1; PTGS2; EGFR |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 8.893E-03 | 1.617E-02 | PDGFRB; ADORA2A; ERBB2; EGFR |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 8.559E-03 | 1.572E-02 | STAT1; SRC; AKT1; MAPK1 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 2.489E-02 | 4.000E-02 | CSNK2A1; SRC; AKT1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.177E-02 | 3.595E-02 | STAT1; AKT1; MAPK1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.313E-02 | 2.294E-02 | GSK3B; INSR; AKT1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.848E-02 | 3.109E-02 | INSR; AKT1; IGF1R |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.378E-02 | 2.363E-02 | ACHE; AKT1; MAPK1 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 1.695E-02 | 2.879E-02 | ADORA2A; MAPK1; BRAF |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.157E-02 | 2.042E-02 | SMAD3; AKT1; MAPK1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 8.048E-03 | 1.494E-02 | SRC; MAPK1; EGFR |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.366E-03 | 8.931E-03 | GSK3B; AKT1; MAPK1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 4.366E-03 | 8.931E-03 | STAT1; MAPK1; PTGS2 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 5.255E-03 | 1.028E-02 | SRC; MET; PTK2 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 4.710E-03 | 9.526E-03 | CASP7; CASP1; MAPK1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.163E-03 | 5.192E-03 | AKT1; MAPK1; BRAF |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 3.576E-03 | 7.662E-03 | SRC; MET; EGFR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.726E-03 | 7.890E-03 | CYP1A2; CYP3A4; CYP2C19 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.505E-03 | 5.500E-03 | AKT1; MAPK1; BRAF |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 2.505E-03 | 5.500E-03 | MAPK1; BRAF; IGF1R |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.952E-03 | 4.813E-03 | CASP7; CASP1; HSPA1A |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 3.147E-03 | 6.824E-03 | SMAD3; STAT1; STAT6 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.316E-03 | 3.338E-03 | PKM; INSR; MAPK1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.723E-02 | 4.300E-02 | CASP1; MAPK1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 2.549E-02 | 4.060E-02 | GSK3B; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.958E-04 | 9.861E-04 | MAPK1; BRAF; TP53 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 7.718E-04 | 2.205E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 2.214E-02 | 3.616E-02 | CASP1; TP53 |
| hsa05144 | Malaria_Homo sapiens_hsa05144 | 2.054E-02 | 3.423E-02 | HBB; MET |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.332E-02 | 2.305E-02 | INSR; MAPK1 |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.082E-02 | 1.928E-02 | MAPK1; HSPA1A |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 8.026E-03 | 1.494E-02 | GAA; AKR1B1 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 6.533E-03 | 1.238E-02 | MAPK1; EGFR |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 9.658E-03 | 1.738E-02 | POLB; APEX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.764E-03 | 9.529E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.230E-02 | 3.616E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; BRAF; AURKA; TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | ERBB2; EGFR; EGFR; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; INSR; CA9; ERBB2; EGFR; PLK1 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; IGF1R; ERBB2; EGFR; EGFR; TP53; KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | BRAF; TSHR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Skin infections | L00-L99 | STAT1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
| C00-D49: Neoplasms | Solid tumors | NA | BRAF |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; PKM; CA9; SRC; IGF1R; PTK2; AURKB; AURKA; FLT4; TEK; PDGFRB; MAPK1; ERBB2; EGFR; TP53; KDR; KDR; KDR; PLK1; PLK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; CASP1; PTGS2; PTGS2; PTGS2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; CSNK2A1; CA1; CA9; ACHE; PTGS2; SRC; IGF1R; PTK2; BRAF; BRAF; AURKA; FLT4; EPHB4; TEK; GSK3B; ADORA3; MAPK1; ERBB2; ERBB2; EGFR; TP53; KDR; PLK1 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; ADORA1 |
| C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
| C00-D49: Neoplasms | Breast cancer | C50 | INSR; CA9; IGF1R; ERBB2; ERBB2; ERBB2; EGFR; EGFR; EGFR; KDR; KDR; KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| C00-D49: Neoplasms | Bladder cancer | C67 | ERBB2; EGFR |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | FLT4; EGFR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADORA3; ADORA2A; ADORA1; ADRA2C |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR; KDR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; ERBB2; EGFR; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; BRAF; ADORA2A; ADORA1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; PTGS2; EGFR; KDR; PLK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | INSR; PKM; ADK; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; ADORA2A; ADRA2C; ADRA2A |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | ERBB2; KDR |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR; KDR; KDR; KDR; KDR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; ERBB2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; AURKA; TP53; TP53; PLK1 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TP53; KDR; KDR |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; INSR; PDGFRB; GSK3B; ADORA1 |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; EGFR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1; ADK |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; PTGS2; PTGS2; ADORA2A; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2; PLK1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; PTGS2; IGF1R; IGF1R; PDGFRB; EGFR; EGFR; KDR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; PTGS2 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; AURKA; PLK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | BRAF; EGFR; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | AML | NA | KDR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; ADRA2C |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; ADRA2C |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| NA: NA | Edema | NA | CA2 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT4; ERBB2; EGFR; PLK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; KDR |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; FLT4; ADORA3; KDR |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; ADORA3 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; PTGS2 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; TEK |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; ADORA2A; ADORA1; ERBB2; ADRA2C |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; TEK; ADORA3 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; PTGS2 |